Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Flagship Pioneering Unveils Expedition Medicines with $50 Million Funding to Expand Small Molecule Drug Boundaries Using Generative Design
_↗ expeditionmedicines.com
News Image

Flagship Pioneering, a renowned scientific innovation engine, recently unveiled Expedition Medicines, a new company dedicated to pioneering the field of generative covalent chemistry to significantly expand the boundaries of treatable diseases. A, a new company dedicated to pioneering the field of generative covalent chemistry to significantly expand the boundaries of treatable diseases. A

fter three years of internal incubation and development, the platform is now supported by an initial $50 million commitment from Flagship to scale its technology for generating small molecule medicines and advance its discovery programs across oncology, immunology, and other well-defined diseases.

Expedition aims to address the challenge of "undruggable" proteins—those lacking the necessary features for traditional, reversible small-molecule binding—by pivoting from a conventional "binding-first" approach to a novel "reaction-first" covalent chemical insight. This groundbreaking method leverages the principles of quantum chemistry to understand and exploit the interactions between small molecules and reactive parts of protein surfaces, enabling high potency binding even in shallow pockets.

The company is building a sophisticated quantum chemistry AI platform, which is fueled by an industry-leading chemoproteomic screening and data generation engine, allowing it to train generative chemistry models to design de novo small molecules against highly elusive targets in the proteome, such as transcription factors, adaptor proteins, and protein-protein interfaces. Co-Founder and CEO Molly Gibson, Ph.D., highlighted that this approach is transforming drug design by learning the rules of molecular reactivity to make small molecule programmability a reality. Demonstrating its immediate application, Expedition has already initiated a multi-target exploration agreement with Pfizer, established under Flagship’s strategic partnership, to identify novel therapeutic candidates for previously undruggable targets implicated in prostate cancer disease progression and treatment resistance.

Log In
Sign Up